Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo.
about
VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesisSturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQUnderstanding venous malformations of the head and neck: a comprehensive insight.Tuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth.Kaposiform hemangioendothelioma: therapeutic efficacy for an enigmatic diagnosis.Endothelial cell-specific chemotaxis receptor (ecscr) promotes angioblast migration during vasculogenesis and enhances VEGF receptor sensitivityLeveraging a Sturge-Weber Gene Discovery: An Agenda for Future Research.Loss of NF1 expression in human endothelial cells promotes autonomous proliferation and altered vascular morphogenesis.Phosphoinositide 3-kinase: a new kid on the block in vascular anomalies.Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine SignalingImaging increased glutamate in children with Sturge-Weber syndrome: Association with epilepsy severity.Application of angiogenesis to clinical dermatology.Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination.Epilepsy Mechanisms in Neurocutaneous Disorders: Tuberous Sclerosis Complex, Neurofibromatosis Type 1, and Sturge-Weber Syndrome.mTOR inhibitors as a new therapeutic option for epilepsy.GNAQ Mutation in the Venous Vascular Malformation and Underlying Brain Tissue in Sturge-Weber Syndrome.Combined blockade of AKT/mTOR pathway inhibits growth of human hemangioma via downregulation of proliferating cell nuclear antigen.Gorham-Stout Disease of the Skull Base With Hearing Loss: Dramatic Recovery and Antiangiogenic Therapy.
P2860
Q24658393-E89C1EB1-4891-44B0-AB15-6505C9D7561DQ28290315-209C601D-34E4-45A7-B73D-7F17B9960A96Q30235992-8FFF961E-DA93-4F1A-831B-847F0E0411F4Q30248734-075AE13F-952E-4AAD-A405-B2672DC4641CQ33419609-2F0F180A-2D5D-48D6-8D96-9A9252857DDCQ33896702-88AC986D-3147-4EB1-8550-21A1BFECCBF3Q33902151-D0B1C560-5D35-4E53-955C-591FE9C3DD97Q34474278-E623D993-1CEB-4E56-BC84-F8FB58FD6946Q36117648-2EA0C8C7-F717-4DA7-849C-81F5B371C930Q36788733-63F8A09B-1B77-4306-A4A5-1FB90D6841C8Q36811083-E8932699-487C-42EE-AE7D-6FBE3282731DQ37079239-ABFDE20E-C4B7-4661-BB3E-D880AB615572Q37377107-731A8E51-46DA-47F4-B6F0-1C19416CE3A3Q37707250-61A3CC8C-068C-473E-A778-47976C1CF424Q38112211-1CE65540-8AD8-41C6-BF26-288F9BE50DDCQ41635567-6E455023-E538-4ED3-98F5-D7DB41BD144BQ44297831-291AA4F8-786B-4AA5-B01B-3A3F638845D5Q50317318-4223FFB7-6666-4BED-BDC5-1E1B5EE2BB69
P2860
Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Mammalian target of rapamycin ...... ascular malformations in vivo.
@en
type
label
Mammalian target of rapamycin ...... ascular malformations in vivo.
@en
prefLabel
Mammalian target of rapamycin ...... ascular malformations in vivo.
@en
P2093
P356
P1476
Mammalian target of rapamycin ...... ascular malformations in vivo.
@en
P2093
Cynthia Cohen
Farheen Shirazi
Jack L Arbiser
Levi Fried
P304
P356
10.1089/LRB.2007.1012
P577
2007-01-01T00:00:00Z